Recent Posts
Deals•Feb 23, 2026
Guardant Health Acquires MetaSight Diagnostics for $59M Upfront
Guardant Health announced the acquisition of MetaSight Diagnostics for $59 million in upfront cash, with up to $90 million in additional contingent payments tied to commercial performance and regulatory approvals. The deal expands Guardant’s multi‑disease detection pipeline beyond oncology, adding MetaSight’s mass‑spectrometry multi‑omics blood test technology. The acquisition was disclosed on Feb 23 2026.
MedTech Dive
Deals•Feb 12, 2026
Neurent Medical Raises $74M in Series C Round to Commercialize Chronic Rhinitis Device
Neurent Medical announced a €62.5 million ($74 million) Series C financing to accelerate commercialization of its Neuromark radio‑frequency device for chronic rhinitis. The round was led by MVM Partners with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and...
MedTech Dive
Deals•Feb 11, 2026
Labcorp Closes $250M Acquisition of Empire City Laboratories Assets
Labcorp announced the closing of its acquisition of assets from Empire City Laboratories, paying $165 million upfront with up to $85 million in milestone payments. The $250 million deal expands Labcorp’s patient service center network in New York and positions it as the integrated...
MedTech Dive